Roche, the Swiss pharmaceutical giant, is investing big in the United States. Roche on Tuesday announced that it would invest $50 billion in the U.S. over the next five years, amid concerns about the impact of possible new White House tariffs on pharma goods from foreign countries.
The investment will create more than 12,000 jobs, Roche said in a media release — 1,000 with the company, and the remainder to support new U.S. manufacturing capabilities. Roche is already known to employ over 25,000 people in America.
READ: Trump to implement tariffs on semiconductors, pharmaceuticals and auto (February 19, 2025)
Roche CEO Thomas Schinecker said in a statement on Tuesday that the company’s new $50 billion investment demonstrated its “long-standing commitment to research, development and manufacturing in the US.”
“We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions,” he said. “Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”
What is Roche?
Roche, officially known as F. Hoffmann-La Roche AG, is a global healthcare company based in Basel, Switzerland. It operates in two main areas: pharmaceuticals and diagnostics. In pharmaceuticals, Roche focuses on treatments for cancer, autoimmune diseases, infectious diseases, and neurological disorders. Its well-known drugs include Herceptin, Avastin, and Actemra. In diagnostics, Roche is a global leader in in vitro diagnostics, providing testing systems used in hospitals, labs, and clinics around the world. Products like the Cobas series are widely used for disease detection and monitoring.
Founded in 1896, Roche has a strong legacy in medical innovation and plays a major role in research and development. It operates in more than 100 countries and employs over 100,000 people. Uniquely, a large portion of Roche is still owned by the founding Hoffmann and Oeri families. The company is known for its strong commitment to science and personalized healthcare.